Status:

UNKNOWN

Observing the Relationship of Fibroblast Growth Factor and Fibroblast in Thyroid Eye Disease

Lead Sponsor:

National Taiwan University Hospital

Conditions:

Graves Ophthalmopathy

Eligibility:

All Genders

20-80 years

Brief Summary

Graves' orbitopathy (GO) affects about 50% of patients with Graves' disease (GD), and some cannot be cured by current treatments. Orbital fibroblasts involves in the pathogenesis of GO by producing gl...

Eligibility Criteria

Inclusion

  • diagnosed as thyroid eye disease
  • suggested to accept orbital decompression

Exclusion

  • age below 20 or above 80
  • pregnancy

Key Trial Info

Start Date :

December 25 2014

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 25 2020

Estimated Enrollment :

80 Patients enrolled

Trial Details

Trial ID

NCT03324022

Start Date

December 25 2014

End Date

December 25 2020

Last Update

October 31 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

National Taiwan University Hospital Taipei, Taiwan

Taipei, Taiwan